Bharat Parenterals Limited is a fully integrated pharmaceutical company based in Gujarat manufacturing world-class affordable medicines for the world. The company is over 30 years research-driven pharmaceutical company with a dedicated facility for the manufacture of antiretroviral drugs and an extensive spectrum of pharmaceutical formulations.
The company is engaged in efficient research, development, manufacturing, marketing, sourcing, and distribution of high-quality pharmaceutical products. Its clients range from small biopharmaceutical players to some of the world’s largest pharmaceutical companies.
Bharat Parenterals Limited has its manufacturing facility at Village Haripura, Taluka Savli at Vadodara, Gujarat where it houses its state-of-the-art manufacturing facility for General Products, β-Lactum/ Cephalosporin Products, Formulations in the form of Tablets, Capsules, Liquid-orals, Ointments, Creams, Lotions and most importantly Powdered Injections and small Volume parenteral both in Ampoules and Vials.
The company has developed and established its own state-of-the-art Formulation and Development center which has been recognized by the Department of Scientific and Industrial Research (DSIR), New Delhi, and is fully equipped with modern sophisticated equipment for new product development as well as scaling up of the products as per customer specific requirement most constructively and innovatively under qualified and experienced technical staff. From a world perspective, Global medicine spending is said to reach USD 1.9 trillion in the next five years with certain key themes to have a great impact on growth and profitability.
The key themes in the generic finished dosage formulation space are geographic focus on the high growth and stable pricing in emerging markets which are expected to experience higher growth in spending and volume than other developed markets. Population-driven volume and a shift towards more expensive medicines because of improved healthcare penetration and rising per capita income are expected to drive emerging market growth.
Other key trends are superior margin fewer competitors in niche portfolios and strong branded generics enjoying stable market share and pricing power. Bharat Parenterals Limited reported decent quarterly financial results with Net Sales at Rs 59.82 crores in December 2023 up 1.36% from Rs. 59.02 crores in December 2022 with Quarterly Net Profit at Rs. 3.64 crores in December 2023 up 27.72% from Rs. 2.85 crores as in December 2022. The EBITDA stood at Rs. 7.88 crores in December 2023 up 28.76% from Rs. 6.12 crores during December 2022. The company reported increased EPS to Rs. 6.45 in December 2023 from Rs. 4.94 in December 2022. The Bharat Parenterals Limited stock currently quoting at Rs 1122 on the bourses can be purchased by long-term portfolio investors for solid gains on the back of decent financial numbers in the next few quarters.